Filing Flows › Pulse Biosciences (PLSE) › Q1 2026
Pulse Biosciences (PLSE) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 14, 2026
Pulse Biosciences (PLSE) reported revenue of $401K for the first quarter 2026 (Q1 2026) and +52% from the quarter before.
Pulse Biosciences, Q1 2026: revenue $401K, net loss $18.6M, operating cash flow −$14.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $401K | +52% | — |
| Operating profit | −$19.1M | — | — |
| Net earnings | −$18.6M | — | — |
| Operating cash flow | −$14.6M | — | — |
What changed
Revenue was $401K in Q1 2026, up 52% from the previous quarter.
Operating costs exceeded revenue by $19.1M, an operating margin of -4775.6%. The quarter ended with a net loss of $18.6M, wider than the previous quarter's $17.4M loss.
Operating cash flow was −$14.6M. Non-cash charges added back $255K of depreciation and amortization and $1.9M of share-based compensation. Working capital and other items added $1.8M. Capital expenditures of $33K exceeded it, leaving free cash flow of −$14.6M.
Questions
What was Pulse Biosciences' revenue in the first quarter 2026?
Pulse Biosciences (PLSE) reported revenue of $401K for the first quarter 2026 (Q1 2026) and +52% from the quarter before.
Source: Pulse Biosciences 10-Q on SEC EDGAR.